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Research is ongoing all over the world for identifying the barriers and finding effective 
solutions to accelerate the projection of Precision Medicine (PM) in the healthcare industry. Yet 
there has not been a valid and practical model to tackle the several challenges that have slowed 
down the widespread of this clinical practice. This study aimed to highlight the major 
limitations and considerations for implementing Precision Medicine. The two theories Diffusion 
of Innovation and Socio-Technical are employed to discuss the success indicators of PM 
adoption. Throughout the theoretical assessment, two key theoretical gaps are identified and 
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With the availability of healthcare big data and technological advancement, clinical practice 
going beyond the “one-size-fits-all” approach. Where emerging the new clinical decision-
making, minimizes medical errors, cuts the cost of overtreatment, increases the quality of 
services offered by care providers, and saves more lives[1]. 
 
Precision medicine is an emerging approach in medical decision-making that takes into account 
individual genetic profile, environmental and lifestyle indicators.  In 2015 the former president 
Obama, launched the Precision Medicine Initiative (PMI) aiming to improve the tailoring of the 
treatment based on individual variables[2]. PMI intends to motivate individuals to cooperate as 
co-researcher to manage their health by sharing their health data (e.g., genomic, genetic, 
longitudinal health information) throughout a  trustful partnership platform, where, this 
cooperation results in obscuring the boundary between health and disease [3]. 
 
Projecting this approach requires early diagnosis, prevention, and tailor the treatment for the 
individual patient. Based on that, sharing data and linking individual patient variables to health 
records are expected to lead to the right drug, at the right dose to the right patient [4]. Hence, 
successful adoption of PM has been found in tailoring treatment to a particular patient subgroup 
with common molecular characteristics [5]. 
 
For the clinical application of precision medicine to be able to fit the patient with matching 
treatment modalities, the incorporation of various heterogeneous parameters is required. 
Although research is underway around the world to speed up progress on precision medicine 
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projection, and there are research programs such as the “All of Us Research”that provide 
innovation opportunities to address the limitations and solutions[3], still, there has not been a 
clear protocol and business model for emerging the PM in healthcare. 
 
The need for collecting individual patient data (e.g., genomes, biological indicators, 
demographics, administration) and integrating them into the Electronic Health Records (EHRs), 
identifying suitable approaches and techniques to deal with big data, transforming large, 
multimodal data into Machine Learning (ML) algorithms for decision-making [6],[7], dealing 
with data protection security and ethical issues of sharing such sensitive data, adopting standards 
for data exchange, empowering stakeholders with education, and proposing effective pipelines 
for restructuring the policies and regulations are some of the considerations for employing PM. 
  
This study aimed to propose the major limitations and considerations for adopting PM in 
healthcare. The paper first explains two theories, which have been used widely by literature to 
address remarkable indicators for successful implementation of Information Systems (IS). After 
that, the main limitations and challenges for projecting PM are highlighted and finally, the paper 
is ended by a discussion throughout examining both theories in implementation of PM. In this 
assessment, we identified two considerable limitations and gaps, which are not taken into the 
account by both theories: DoI and Socio-tech. 
 
2. THEORETICAL FOUNDATION 
 
The aspects of adoptinginnovation/ technology have been studied for over 30 years, and literature 
has used multiple theories to address the success indicator for adopting new technology. The 
theoretical basement of this study highlights the general consideration of Information Systems 
(IS) adoption through the Socio-technical theory and Diffusion of Innovation (DoI). Where both 
theories have been widely used in scientific research from a broad variety of disciplines [8]. 
 
2.1. Socio-Technical Theory 
 
According to figure 1, the socio-technical theory emphasizes that the information system contains 
two major interrelated subsystems: the technical and social. Whereas technical aspects address 
tangible factors such as technology and tasks required to convert system inputs into out- puts, 
social aspects mostly concentrate on organizational aspects, people and the perfect harmony 
















Figure 1. Socio-Tech Paradigm 
Social aspects :
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2.2. Diffusion of Innovation Theory 
 
From IS perspective, Diffusion of Innovation (DoI) expresses major indicators for successful 
adoption: compatibility ( degree in which the new technology is compatible with the existing 
system), technical complexity(how easy/difficult is the technology to understand), the relative 
advantage of adopting the technology (the degree to which an innovation adds value to an 
existing system), triability (to what extent the innovation can experiment before adoption), and 
observability (how the innovation provides tangible results)[9],[11]. 
 
Roger defines diffusion as the process that innovation is communicated via specific channels 
over time and through the member of a social platform; he used the word “technology” and 
“innovation” interchangeably [8]. Thus, not only technological aspects of innovation affect a 
successful adoption, but also, social platform and communication including, people, policies, 
regulations, and management influence this process. 
 
3. PRECISION MEDICINE 
 
Healthcare and medicine industries are facing dramatic changes under the influence of Artificial 
Intelligence (AI) techniques, Business Analytics (BA). The huge amount of data is challenging 
the business model of empirical medicine [1], where, answering the questions such as why does a 
drug work for some patients and be less effective on others? Why does medicine cause side 
effects on some individuals? Why do cancers influence some people and do not others? need The 
medical practice of tailoring each patient as a unique case. 
 
On January 20, 2015, former President Barack Obama announced the great potential health 
improvement to science. The “Precision Medicine” launched by him, has been a remarkable 
research opportunity in a new area of medical practice for improving public health; “Tonight, I’m 
launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer 
and diabetes and to give all of us access to the personalized information we need to keep 
ourselves and our families healthier.”; Hence the new approach to medical practice includes two 
components; a short-term which concentrates on cancer diseases and the long-term that considers 
other illnesses [4]. According to the U.S. National Library of Medicine, “Precision Medicine” is 
an emerging approach that considers individual differences such as genes, environment, and 
lifestyle for preventing and treating particular diseases [4], [12]. Furthermore, the institute of US 
National Cancer defines Precision Medicine as “a form of medicine that uses information about a 
person’s genes, proteins, and environment to prevent, diagnose, and treat disease” [13]. 
Moreover, the approach of PM is the category of medical sciences that aims to predict the 
possibility of developing a disease, achieve a precise diagnosis, and optimize the best 
performance of treatment for a particular patient [14]. In other words, according to figure 2, 
precision medicine intends to consider individual patient variables in terms of genetic, lifestyle, 
and environmental effects also distinguishing patients from other patients with the same 
presentations for improving the clinical practice, minimizing side effects, and increase the 





















Figure 2. Precision Medicine 
 
4. BARRIERS of PRECISION MEDICINE ADOPTION 
 
4.1. Characteristics of the Domain 
 
4.1.1. Adoption of Classification Systems and Clinical Terminologies 
 
Although terminologies that contribute to PM have been built using ontologies (a form of 
reasoning through logics for classifications), the challenges related to the employment and 
integration of them in healthcare is one of the major barriers that strongly affect the development 
of PM application [16], [17]. 
 
Lack of nation-wide projects and less completed projects of implementing ontology-based, 
terminologies have caused the stakeholders to avoid solid conclusions about the projection of 
ontology-based terminologies. Moreover, the lack of experts in biomedical ontologies and the 
semantic web are another limitation for PM development. As a result, the architectures to fully 
integrate different types of ontologies are still immature. This lack of large developments 
resultsin a high risk when designing EHR systems that use multiple ontologies since a large 
number of terminologies and ontologies have been developed in parallel by different bodies, thus 
making ontology mapping among them extremely challenging[18], [19]. 
 
4.1.2. Limitations in Clinical Evidence, Outcomes, and Value Assessment Practice 
 
Whereas, technologies are employed to develop the new approach of Medical Decision Making; 
PM,  insufficient information, successful clinical evidence, and unavailability of universally 
adopted data models for validating the practical work have not guaranteed the value and outcome 
of PM [16]. 
 
4.1.3. Adoption of Standards for Data Collection and Integration- Clinical Data Exchange 
 
There have been various limitations and challenges in laboratory, medication, diagnosis, 
radiology, pathology, clinical evidence & outcomes, and procedures, based on the availability of 
different data structures and related challenges of adopting the existing standards for data 
exchange. For example, incorporation of genetic results into EMR in a searchable way. 
Moreover, in many cases, tests, which are conducted in external labs, cannot be integrated into 
other systems. Differences between lab code systems and identifications or missing the genetic 
info in EHRs data are some of the key challenges related to the data exchange [16]. Furthermore, 
identifying the right moment for clinical data exchange becomes a competitive process that needs 
attention [20].  
Individual’s Variables Tailoring the Treatment 
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The researchers have identified the need of extending the scope of the existing standards rather 
than inventing a new one where data standardization for integration and exchange is required for 
the correct interpretation of the data elements. 
 
Although various initiatives have worked in this line to facilitate the adoption of the data 
standards especially in the omics discipline such as BioSharing, (works to ensure the standards 
are searchable and informative.), to extend the existing standards, the relevant stakeholders 
should cooperate to educate the potential adopters for understanding and using the existing data 
standards [21]. 
 
4.1.4. Data Processing and Storage – Handling Big Data 
 
The speed of generating a massive amount of data from various resources has not been balanced 
with big data management yet. The analysis and processing of such data need hardware and 
software facilities, which is beyond the local infrastructures of many small laboratories. 
Particularly, molecular and omics data analysis requires powerful computational tools 
[21].Whereas componential resources and related facilities require a high cost of maintenance 
and development [6], adopting technologies such as cloud computing and the Internet of Things 
(IoT)can be an alternative to deal with the high cost of storage and computational requirements. 
For example, Siemens Healthcare, Philips Healthcare, and GE Healthcare are the three big 
medical imaging companies that pioneered switching computer-intensive image processing to the 
Health Cloud ecosystem. Together they have developed a strategy for establishing an “All-in-one 
Health Cloud” to provide the unique cloud platform [2], [22]. Although cloud computing can be a 
potential solution to deal with big data management issues, the need for protecting healthcare 
data and applying security and privacy levels will be increased[6], [23]. To deal with this 
requirement, solutions such as access control models and blockchain technology are offered. 
However, each solution carries specific limitations, which need to be addressed. For example, 
access control models, which perform based on the access authorizations and defined regulations, 
are less effective against internal risk attacks. Hence, in many cases, hybrid approaches are 
applied to integrated access control with some other methods such as encryption.  Moreover, 
Blockchain technology is another alternative for secure data management in cloud platforms 
where the possibility to delete or modify stored data is almost zero. This characteristic of 
blockchain criticizes the regulations of personal data privacy; when it is obligated to delete the 
personal data based on individual patient’s rights. Hence, in this case, blockchain technology 
requires to solve these types of challenges through new policies, privacy models, and further 
studies[24]. 
 
4.1.5. Ethical and Legal Literature for Open Data Exchange 
 
Data protection, security, and related ethical issues are another challenge. Personal health data is 
sensible and valuable. It has been estimated that the healthcare domain is 200 % more likely to 
experience a data breach than other industries. Moreover, because data generated modular via the 
internet and in many cases stored offline, ethical consideration prevents an open data exchange 
[6]. For example, unintended access (the misuse of information gained through unauthorized 
access) is a serious challenge when it reaches to debating about ethical issues [25]. 
 
Due to the reforming of the medical domain as the data-sharing community, the patient’s role as 
the owner and manager of her/his health data became more valid. Thus changing the power 
between care providers and care receiver is considerable needs restructuring regulations and 
policies.  On one hand, the patient is requested to share personal information, on the other hand, 
it gives the right to the individual to become a member of the data-sharing community thus the 
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roles, responsibilities, and authorities need restructuring and ethical issues should be addressed in 
an effective way [3]. 
 
4.1.6. Features of Healthcare Data  
 
For PM, the major data include EHRs and Omic. Big Omic data contains a comprehensive 
catalog of molecular profiles (e.g., genomic, transcriptomic, epigenetic, proteomic, and 
metabolomics) and EHRs contain structured and unstructured clinical data. Both Omic and EHRs 
are challenging for analytics because of the data frequency, quality, dimensionality, and 
heterogeneity. Moreover, EHRs include structured data (e.g., ICD-9 diagnosis codes, 
administrative data, charts, and medication) and unstructured (e.g., clinical notes). Structured 
data includes two classes: administrate data, which remain unchanged during the entire clinical 
process. For example, demographics are administrative data. The second class is ancillary clinical 
data; the data, which frequently or continuously recorded during the clinical process such as 
medications and lab tests of blood pressure monitoring via sensors. This heterogeneity of data is a 
considerable challenge for data analysis[26]. Furthermore, in omic data, the combination of 
biological, instrumental, and environmental factors affects the quality of data. In EHRs, the 
quality of data depends on the missing data and incorrect records, which are the consequences of 
the clinician’s teamwork to enter data, miss-interpretation, and the organization of  documents for 
data entry.  Hence, any mistakes and misinterpreting will cause wrong conclusions and inaccurate 
decision-making [26]. 
 
4.1.7. Adoption of Genomics in EHR (eMERGE)  
 
Adoption of PM requires the integration of EHRs and Genomics (eMERGE). In a clinical setting, 
EMR (Electronic Medical Records) is used for clinical decision support and the integration 
between genomic/genetic data and EMR identifies causal genomic variants and genotype-
phenotype associations into the EMR system. The major challenge of such integration is finding 
the most suitable method for storing and reprocessing the variants present in an individual or 
even family and the next generation in EMR. Moreover, for integrating genetic/genetic data into 
the EHRs, the size of genetic/genomic laboratory test results and the limited capacity of EHRs 
also has been identified as significant limitations. Because each individual has millions of 
variants and the variation of genomic data cannot fit into the current design of EHRs. One 
potential solution is to archive raw data in separate data repositories to be accessible once it is 
requiring. However, storing such unstructured data makes the processing speed slow. Another 
alternative is to strategize the external genetic/genomic data warehousing. In this approach, data 
is stored external to EHRs and the link connect and integrate particular record to related EHRs 
record [27]. 
 
In the addition, the genetic records stored in EHRs need to be interpreted throughout the clinical 
terms and vocabularies. To tackle this challenge, a couple of solutions have been suggested such 
as using rule-based decision support systems and using visualization elements for better 
presentation. 
 
Besides, EHRs include medical records of all participants and hospitals, while EMR contains 
limited data for local clinics and hospitals. Therefore, standardizing the data exchange and 
defining protocols for better interoperability is useful for effective treatment [26]. Moreover, in 
addition to the technological challenges for adopting genomic/genetic in EHRs, the 
environmental aspects such as ethical and legal boundaries for data sharing and such integration 
need attention[17], [28]. To support the adoption of PM, various countries propose practical 
policies to protect individual’s genomic/genetic data from discrimination to assure the patient 
about the security and privacy level of their data [29].  
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4.1.8. Research and Practice  
 
Many research works have discussed the effective role of AI/ML for early diagnosis and better 
treatment, but also the relevant challenges have been addressed. Since projecting such approaches 
is still in the development stage, the lack of understanding of AI and ML is a limitation, and 
identifying the most effective approaches for pioneering valid clinical practice of PM needs more 
scientific research and practice [16]. Furthermore, the techniques for automating data collection, 
analysis, and processing are usually projected locally, and transferring the success story to other 
healthcare providers is not easy [6]. 
 
To speed up the delivery of precision medicine, more research is needed, particularly in the 
following biomedical big data areas and omics data integration. The big omics data analysis, for 
example, provides a holistic view for analyzing the patient condition and for effective prediction 
[26]. in many cases, applied research environments and academia have faced limitations and 
challenges to accessing healthcare data, in terms of privacy and security. Thus, Protected Health 
Information (PHI) and lack of trust are some of the critical issues that affect the development of 
research works in this area [16].  
 
The second area in which research and practice demonstrate the influential effect is Patient 
segmentation based on similarities. Classifying patients based on biological similarities on their 
profile is a crucial phase in developing PM. Therefore, data mining applied in EHRs us clinical 
indicators such as drug responses, physiological signals, and disease susceptibility for patient 
classifications. However, high patient variability for disease and also the fact that many 
subgroups of the disease have not been identified yet, affect the performance of the practical PM 
application. Hence, this gap needs systematic research for validating the classifications of the 
patient based on EHR mining [26].  
 
Finally, as was discussed above, healthcare requires strong clinical evidence to analyze the 
validity of precision medicine in practice. This requirement is completely important for expanded 
clinical use [5]. Therefore, to address the limitations, it is required to develop secure research-
based frameworks for efficient data collection, data integration, storage and pre-processing, de-
identification to serve a large community of users, support organizational policies, and provide 
efficient access and connectivity [16]. Such as a new research platform that minimizes the 
isolation between scholar platform and clinical data [21]. 
 
4.2. Lack of a Unique Definition of Precision Medicine 
 
Although Precision Medicine is in use as a common label, by many public funding streams (e.g., 
Genome England, Australian Genomics, and the Center for Personalized Cancer Treatment in the 
Netherlands) and private funding streams (e.g., IBM Watson), but the terminology is still 
evolving, and multiple terms have been used interchangeably literature has used various terms 
such as 'pharmacogenomics' and 'P4 medicine' (preventative, predictive, participatory, and 
personalized),  to point out different aspects of the relevant research about precision medicine. 
Whereas all of these conceptualizations seem to perform in the same direction [3], the lack of the 
unique terminology may lead to misunderstanding by the stakeholders who have the power and 
responsibilities and different roles in accelerating PM adoption [5], [30]. 
 
5. EXAMINING THEORIES; DISCUSSION and FINDINGS 
 
From the socio-tech theory perspective, in the implementation of PM application two subgroups 
play a critical role: technological and social. Also, the effective balance between the two aspects 
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grantees success. Moreover, as we discussed above, the diffusion process requires, innovation to 
be communicated in time through social channels. Combining the major success indicators of 
these two theories for examining PM application implementation, we conclude that the PM 
application as the innovation/technology needs to be assessed in terms of the degree of its 
compatibility with existing systems in healthcare (e.g., workflows, business processes, 
hardware/software infrastructures and resources). Moreover, the benefit and advantages of using 
this technology should be identified and communicated widely via a social platform, where the 
power and role of stakeholders’ networks are remarkably important. Besides, identifying the 
complexity, reliability, and observability of this technology needs to be evaluated via a defined 
research platform where the effective cooperation between academia, the healthcare industry, and 
technology providers results in trust and confidence to achieve the outcome of technological 
evaluations.  
 
From the social and organizational point of view, as it was discussed in both theories, 
management support, effective communication, educating people, pipelining strategic plans for 
tackling the environmental pressures such as boundaries and policies make the diffusion smooth 
clear, and rewarding. 
 
The adoption of precision medicine not only will affect many health systems, but also all 
stakeholders.  (e.g., Individual patients, care providers, policymakers, technology providers, drug 
developers). Therefore, each level of stakeholders carries specific preferences, definitions, and 
the requirement for accepting the new innovative technology (PM); proposing the value 
assessment of the PM can be an alternative to link stockholders and facilitate and strategies 
education and communication required for new technological adoption. 
 
Although the socio-tech and DoI, both address the social, organizational, and technological 
indicators in total, these two theories carry gaps. The limitations are identified where the 
characteristics of the domain and the vital needs for research and practice are discussed. As table 
1, demonstrates, without solving the problems carries by healthcare (e.g., projection of 
terminologies and classifications, integrating genomes in EHRs, adopting standards for data 
exchange, challenges about data features, data security, and ethical issues, dealing with big data, 
selecting the most effective approaches), the emerging of PM will not be projected successfully. 
Moreover, presenting evidence-based validity, value assessment, proposing the unique and 
fashionable term and definition for PM, and identifying the most effective techniques and tools 
for data analysis, data extraction, and mining to fulfill the PM approach requires research and 
practice. This cooperation needs inputs from other disciplines such as biomedical research, 
statistics, economics, and ethics, and key health stakeholders; where, in practice, the interplay 
between several stakeholders should be taken into the account[5], [30], and finally, empowering 
patients, doctors and public, as the co-researcher about PM accelerate the adoption process. 
Making PM comprehensible, trustworthy, and equally accessible for the population as the 
participatory opportunities for people to participate in the production of data for the good of 
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Table 1. Major considerations and limitations of PM adoption 
 
 
As a result, based on identified limitations of both theories (DoI, socio-tech) in IS 
implementation, figure 3 presents the final influential indicators for emerging PM adoption in 
healthcare. Where the two new aspects: “research & practice” and “characteristics of the domain” 



















Figure 3. Success Indicators for PM Implementation- Theory Assessment 
 
In summary, it can be concluded that PM is applicable to be introduced as socio-tech /DoI 
phenomena.  Therefore, for integrating PM in healthcare, not only managerial and organizational 
 
 





























































Adoption of classification systems and clinical terminologies   X X 
Limitations in clinical evidence & outcomes X   X 
Adoption of standards clinical data exchange   X  
Data processing and storage – handling big data   X  
High security, ethical and legal literature X  X  
Features of healthcare data(format, quality)   X  
Adoption of genomics in EHRs (emerge)   X  
Selecting the most effective approaches-techniques   X X 
Patient segmentation based on similarities    X 
Lack of a unique definition of PM X   X 
Management aspects 
Education and skills 
Communication 
Environmental pressures (policies, regulations) 
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aspects needs to be addressed, but also the technical issues such as the unique definition of PM, 
reliability, and complexity needs considerations. 
 
Besides, there are major limitations, which are directly related to the features of the healthcare 
ecosystem itself. As is mentioned above, since healthcare is a data-driven platform, therefore, 
limitations and challenges carry by the characteristic of data (eg., sensitive, fragmented, 
heterogeneous, unstructured, high volume) strongly influence this transition.  For example, we 
discussed the possibility of employing the cloud computing solution to deal with big data 
management in terms of storage management and maintenance, it is also discussed the limitations 
that cloud computing presents in terms of security and data protection. Moreover, where 
blockchain technology can deal with security and data protection, the role of individuals as the 
owner of data and their willingness for data sharing, open another limitation. Besides, not only 
data characteristics are a matter but also the complexity of the domain with interconnected 
entities provide complicated regulations that need attention. For example, projecting PM in 
healthcare needs a trustful cooperation platform for data sharing by empowering individuals to 
participate in their health management purpose.  However, such an arrangement demands a deep 




This paper discussed the key limitations and considerations for emerging Precision Medicine in 
healthcare. Although there have been various terms used interchangeably as PM, it is introduced 
as a new approach in medical decision making where the individual patient variables in genetics, 
lifestyle, and environmental are taken into the account. This study employed the socio-tech and 
DoI paradigms to explain the various technological (e.g., complexity, compatibility, trialability, 
tangibility, perceived value), social-organizational (communication, education, cooperation, 
management), and environmental (e.g., policies, regulations, ethical issues) indicators which 
influence the successful implementation. By examining the combined theories (socio-tech, DoI), 
the PM application is presented as a socio-tech and DoI phenomena through this 
theoreticalassessment, we identified two critical aspects, which are missed to address by both 
theories: “characteristics of healthcare” and “research and practice under a cooperative model of 
partnership and trust”. Accounting for these two identified aspects enables us to deal with the 
limitations and difficulties we have faced in a complex domain like healthcare. Besides, to 
facilitate the transition through valid clinical evidence and value assessed outcomes of PM 
practice. Successful adoption of PM in healthcare contributes to maximizing the quality of 
treatment and saving more lives by minimizing medical errors, decreasing the risk of over-
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